Thermo Fisher Scientific Inc (LIM:TMO)

$ 607.5 0 (0%) Market Cap: 211.04 Bil Enterprise Value: 239.71 Bil PE Ratio: 34.85 PB Ratio: 4.34 GF Score: 95/100

Q2 2024 Thermo Fisher Scientific Inc Earnings Call Transcript

Jul 24, 2024 / 12:30PM GMT

Release Date Price: $533

Transcript 10-Q8-K

Key Points

Positve

Thermo Fisher Scientific Inc (TMO) reported strong financial results for Q2 2024, with revenue of $10.54 billion and an adjusted operating income of $2.35 billion.
The company achieved a 4% year-over-year increase in adjusted EPS, reaching $5.37 per share.
Thermo Fisher Scientific Inc (TMO) raised its 2024 guidance, now expecting revenue between $42.4 billion and $43.3 billion and adjusted EPS between $21.29 and $22.07 per share.
The company launched several high-impact new products, including the Thermo Scientific Stellar mass spectrometer and new additions to the Thermo Scientific Orbitrap Ascend Tribrid mass spectrometer portfolio.
Thermo Fisher Scientific Inc (TMO) continues to strengthen its industry-leading commercial engine and trusted partner status with customers, expanding clinical trial supply services and opening new innovation labs.

Negative

Revenue in the pharma and biotech segment declined in the low single digits due to the vaccine and therapy revenue runoff, resulting in a four-point headwind.
The diagnostics and healthcare segment also saw a decline in revenue in the low single digits, impacted by the runoff of COVID-19 testing-related revenue.
North America experienced a mid-single-digit decline in revenue, indicating regional challenges.
The laboratory products and biopharma services segment saw a 1% decrease in both reported revenue and organic growth, driven by the runoff of vaccines and therapies revenue.
Adjusted operating margin for the laboratory products and biopharma services segment was 12.9%, 120 basis points lower than Q2 2023, reflecting unfavorable volume mix and strategic investments.

Operator

Good morning, ladies and gentlemen, and welcome to the Thermo Fisher Scientific 2024 second-quarter conference call. (Operator Instructions) I would like to introduce our moderator for the call, Mr. Rafael Tejada, Vice President, Investor Relations. Mr. Tejada, you may begin the call.

Rafael Tejada

Thermo Fisher Scientific Inc - Vice President - Investor Relations

Good morning and thank you for joining us. On the call with me today is Marc Casper, our Chairman, President and Chief Executive Officer; and Stephen Williamson, Senior Vice President and Chief Financial Officer.

Please note this call is being webcast live and will be archived on the Investors section of our website, thermofisher.com under the heading News Events and Presentations until August 7, 2024. A copy of the press release of our second quarter 2024 earnings is available in the investor section of our website under the heading, Financials.

So before we begin, let me briefly cover our Safe Harbor statement. Various remarks that we may make about the company's future

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.